Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 12.01.2026			% 5 Tage	Veränd. 1. Jan.
3,600 ^USD	-3,49 %		+1,41 %	+2,56 %

19.12.	Rocket Pharmaceuticals, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 07:55 AM
18.11.	Rocket Pharmaceuticals-Aktien nach Herabstufung durch JPMorgan im Minus	MT

Andere Sprachen

05.01.	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
09.12.	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
25.11.	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
18.11.	Rocket Pharmaceuticals Shares Lower After JPMorgan Downgrade
06.11.	Rocket Pharmaceuticals Q3 net loss narrows
06.11.	Rocket Pharmaceuticals: Q3 Earnings Snapshot
06.11.	Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
06.11.	Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
14.10.25	Rocket Pharmaceuticals, Inc. Announces FDA Acceptance of BLA Resubmission of KRESLADI for Treatment of Severe Leukocyte Adhesion Deficiency-I
14.10.25	Rocket Pharmaceuticals Shares Surge after FDA Accepts Drug Application Resubmission
14.10.25	Rocket Pharma Gets FDA Review Date for Severe Immune Disorder Drug Candidate
14.10.25	FDA Accepts Rocket Pharmaceuticals' BLA Resubmission for Rare Genetic Disorder Treatment
14.10.25	Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
13.10.25	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4
13.10.25	Rocket Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
10.10.25	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03.10.25	Rocket Pharmaceuticals, Inc. Announces Withdraw its Biologics License Application to the U.S. Food and Drug Administration
03.10.25	Rocket Pharmaceuticals, Inc. Announces Resignation of Pedro Granadillo from Board of Directors, Effective September 30, 2025
03.10.25	Rocket Pharmaceuticals Pulls FDA Application for RP-L102 Gene Therapy
03.10.25	Rocket Pharmaceuticals Withdraws FDA Application for Fanconi Anemia Treatment
03.10.25	Rocket Pharmaceuticals withdraws US application for blood disorder gene therapy
03.10.25	Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
03.10.25	USA-Les valeurs à suivre à Wall Street (actualisé)
28.08.25	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
25.08.25	Rocket Pharmaceuticals, Inc. Announces CFO Changes

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Biotechnologie

Andere Sprachen

Filter